TCMD

Tactile Systems is a genuinely high-quality small-cap medtech. Revenue has compounded steadily from $208M (FY2021) to $330M (FY2025, +12.5% YoY), gross margin is an enviable 75.9%, and the company swung from losses in 2021–2022 to three straight profitable years. Operating income grew +32% to $29.3M — faster than revenue — signaling real operating leverage as sales-and-marketing spend is absorbed. The balance sheet is pristine: zero long-term debt, $83.4M cash, liabilities/equity of just 0.25x, and $42.8M of operating cash flow against only $2.38M capex, producing ample free cash. Management is returning that cash aggressively — $26.6M of buybacks cut the share count 4.9%, which is why diluted EPS rose +17.1% (faster than net income's +12.5%). This is a well-run, self-funding business.

The problem is price versus the forward risk. At $31.35 the stock trades at 38.2x trailing EPS and ~2.1x sales for a company growing revenue in the low-teens — a PEG near 3. That multiple prices in continued clean execution, yet net margin is still only 5.8% (heavy S&M is the swing factor) and ROE a modest 8.7%, so the earnings base is thinner than the gross margin flatters. Paying nearly 40x for ~12% top-line growth leaves little margin of safety.